Clene Inc. (CLNN) News

Clene Inc. (CLNN): $0.35

0.00 (0.78%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add CLNN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#353 of 367

in industry

Filter CLNN News Items

CLNN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLNN News Highlights

  • CLNN's 30 day story count now stands at 8.
  • Over the past 14 days, the trend for CLNN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about CLNN are CNM, IBN and CL.

Latest CLNN News From Around the Web

Below are the latest news stories about CLENE INC that investors may wish to consider to help them evaluate CLNN as an investment opportunity.

Clene Announces New Data from HEALEY ALS Platform Trial

LOS ANGELES, CA - (NewMediaWire) - December 22, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN) (along with its subsidiaries, "Cl...

Yahoo | December 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | December 21, 2023

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of long-term all-cause mortality (>18 months, p=0.0167) in participants originally randomized to CNM-Au8 30mg compared to those originally randomized to placebo using the rank-preserving structural failure time model (RPSFTM) CNM-Au8 30mg had greater overall treatment effect in delaying the time to morbid

Yahoo | December 21, 2023

Clene Provides Update on ALS Clinical Development Meeting With FDA

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Admini

Yahoo | December 21, 2023

How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

LOS ANGELES, CA - (NewMediaWire) - December 19, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene, a late clinical-stage biopharmaceutical company...

Yahoo | December 19, 2023

Clene Lead Drug Candidate Featured in Peer-Reviewed Publication

LOS ANGELES, CA - (NewMediaWire) - December 15, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN), a late clinical-stage biopharmac...

Yahoo | December 15, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson’s disease with CNM-Au8® treatment Data show significant increase in brain NAD+/NADH ratio from baseline, the studies’ primary endpoint, following 12 weeks of daily oral dosing of CNM-Au8CNM-Au8 treatment resulted in favorable modulation of additional brain energy metabolites that have been shown to be

Yahoo | December 14, 2023

Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients

LOS ANGELES, CA - (NewMediaWire) - December 12, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN), together with its wholly owned s...

Yahoo | December 12, 2023

Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles

LOS ANGELES, CA - (NewMediaWire) - December 8, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.The 2023 Nobel Prize in Chemistry, awarded to Moungi G....

Yahoo | December 8, 2023

Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals

LOS ANGELES, CA - (NewMediaWire) - November 23, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene is focused on developing and commercializing nov...

Yahoo | November 23, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!